Lexology December 23, 2025
Mintz

Since our last update, the Trump administration has continued to pressure pharmaceutical manufacturers to reduce U.S. drug costs. The Trump administration has secured additional deals with pharmaceutical manufacturers, rounding out 2025 by announcing drug pricing agreements with Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These nine new pricing deals add to the growing list of manufacturers willing to agree to the terms set forth in President Trump’s July 31st letters, which already include Pfizer, AstraZeneca, EMD Serono, Novo Nordisk and Eli Lilly.

Nine New Manufacturer Deals to Reshape Drug Pricing

The nine manufacturer agreements announced on December 19, 2025, follow in the footsteps of predecessor deals, with each manufacturer agreeing to reduce, or...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
What’s new with GLP-1s
Navigating the Shift: 2026 Medicare Drug Pricing and the Future of Pharmacy
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model

Share Article